HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women

J Thromb Haemost. 2004 May;2(5):700-1. doi: 10.1111/j.1538-7836.2004.00696.x.
No abstract available

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Coagulation Factors / drug effects
  • Case-Control Studies
  • Cholesterol / blood
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Middle Aged
  • Postmenopause*
  • Pravastatin / pharmacology
  • Pravastatin / therapeutic use
  • Risk
  • Simvastatin / pharmacology
  • Simvastatin / therapeutic use
  • Venous Thrombosis / drug therapy*

Substances

  • Blood Coagulation Factors
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Cholesterol
  • Simvastatin
  • Pravastatin